Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.31
-0.4100-0.13%
Volume:93.65K
Turnover:29.16M
Market Cap:18.73B
PE:33.80
High:313.00
Open:313.00
Low:310.31
Close:311.72
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.62
T/O Rate:0.16%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.50

Loading ...

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

Rici Healthcare Calls EGM to Approve Change of Auditor

TIPRANKS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Singapore General Hospital deploys AI tool to bring brain-bleed scan reports within 30 minutes

Nurdianah Md Nur
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Maybe the Snowbirds are Right? One State Dominates This List of Best Places to Retire.

Dow Jones
·
Sep 19

How an HSA Can Help You Save for Retirement

Dow Jones
·
Sep 19

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Teva presents new new real-world data on uzedy at Psych Congress

TIPRANKS
·
Sep 19

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19